Here are 1-3 brief analogies to describe Armata Pharmaceuticals (ARMP):

• They're like a Moderna or BioNTech for antibiotic-resistant bacteria, using specialized viruses (bacteriophages) instead of mRNA to develop new treatments.
• They're like the Tesla of antibiotics, pioneering bacteriophage therapy to fight "superbugs" and disrupt traditional chemical drug approaches.

• AP-SA02: A bacteriophage therapeutic candidate designed to treat *Staphylococcus aureus* infections, particularly in prosthetic joint infections.
• AP-PA02: A bacteriophage therapeutic candidate targeting *Pseudomonas aeruginosa* infections, primarily for patients with cystic fibrosis.
• AP-PA03: A bacteriophage therapeutic candidate also targeting *Pseudomonas aeruginosa* infections, specifically for patients with non-cystic fibrosis bronchiectasis.

Armata Pharmaceuticals, Inc. (symbol: ARMP) is a clinical-stage biotechnology company focused on developing bacteriophage therapeutics. As a clinical-stage company, Armata Pharmaceuticals is primarily engaged in research and development and conducting clinical trials for its drug candidates.

Due to its current stage of development, Armata Pharmaceuticals does not have any commercial products approved for sale on the market. Consequently, the company does not have "major customers" in the traditional sense of entities or individuals purchasing its commercial products.

The company's operations are typically funded through:

• Investors: Equity financing through the sale of stock.
• Grants and Collaborative Agreements: Funding received from government agencies, non-profit organizations, or partnerships with larger pharmaceutical companies for the research and development of its drug candidates.

If and when Armata Pharmaceuticals successfully develops and gains regulatory approval for its products, its potential future major customers would typically be other companies within the healthcare supply chain. These would include:

• Pharmaceutical Wholesalers and Distributors: Such as McKesson (MCK), AmerisourceBergen (ABC), and Cardinal Health (CAH).
• Hospitals and Healthcare Systems: Entities that directly purchase pharmaceuticals for patient care.
• Pharmacies: Including major retail chains (e.g., CVS Health - CVS, Walgreens Boots Alliance - WBA) and independent pharmacies.

null

Deborah Birx, M.D. Chief Executive Officer

Deborah L. Birx, M.D., was appointed Chief Executive Officer of Armata in July 2023. She is a world-renowned medical expert who most recently served as the response coordinator of the White House Coronavirus Task Force. Previously, she held the position of Ambassador-at-Large, coordinating United States Government Activities to Combat HIV/AIDS and acting as the U.S. Special Representative for Global Health Diplomacy. Dr. Birx also oversaw the President's Emergency Plan for AIDS Relief (PEPFAR) at the CDC as the U.S. Global AIDS Coordinator and was the Director of the U.S. Military HIV Research Program (USMHRP) at the Walter Reed Army Institute of Research. She served in the United States Army from 1980 until 2008, retiring as a colonel. Dr. Birx has published over 230 manuscripts, authored nearly a dozen scientific chapters, and developed and patented vaccines. She previously served on Innoviva's Board of Directors from March 2021 until July 2023.

David House Senior Vice President of Finance and Principal Financial Officer

David House was appointed Senior Vice President, Finance and Principal Financial Officer on August 16, 2024. Prior to joining Armata, Mr. House served as Corporate Controller and Vice President of Accounting at ZO Skin Health, Inc. from October 2018 to May 2024. At ZO Skin Health, he managed global accounting operations, financial reporting, and played a crucial role in the company's acquisition by Blackstone. He also established international subsidiaries and oversaw financial integration for mergers and acquisitions. His experience also includes similar financial leadership roles at Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Avid Bioservices, Inc.

Pierre Kyme, Ph.D. Chief Business Officer

Pierre Kyme, Ph.D., was appointed Chief Business Officer of Armata in June 2024. He is dedicated to Armata's business and corporate development activities, a role he began at C3J Therapeutics in 2015. Previously, Dr. Kyme served as a lead Scientist and Director of Product Development at C3J Therapeutics from 2012, where he led a team in developing an antimicrobial molecule through Phase 2 human clinical trials. Before C3J Therapeutics, he spent five years maturing his drug development career at Cedars-Sinai Medical Center, leading project teams from concept through preclinical research in infectious disease and immunology. Dr. Kyme has also served as Scientific Advisor for Cappello Global, a boutique investment bank, and as a consultant analyst to a global specialist life sciences investment firm. He completed his postdoctoral training at the University of British Columbia under a Gates Foundation grant, developing Innate Defense Regulators.

Peter Hubbard Vice President of Operations

Peter Hubbard is the Vice President of Operations at Armata Pharmaceuticals. He leads Armata's operations team with over 17 years of experience in biotech and pharmaceutical production, having worked with companies such as Baxter Bioscience, GlaxoSmithKline, Pacira Pharmaceuticals, and Kite Pharma. Most recently, he was the Director of Manufacturing at Armata Pharmaceuticals, where he led the manufacturing team starting in 2022 and helped build out greater manufacturing capabilities. Prior to joining Armata, Peter contributed to maturing manufacturing operations at Kite Pharma. He has experience leading Right First Time Initiatives, cost savings projects, and streamlining manufacturing operations.

Bani Tchekanova, Ph.D. Head of Regulatory Strategy and Operations

Bani Tchekanova, Ph.D., was appointed Head of Regulatory Strategy and Operations of Armata in July 2025. Before joining Armata, Dr. Tchekanova served as a Chief Principal Advisor at ClinReg Partners, LLC. She brings over 25 years of diverse and dynamic experience in global drug development and regulatory affairs, with a career spanning a wide array of therapeutic areas, including infectious disease, oncology, dermatology, ophthalmology, cardiovascular, neuroscience, and gene therapy.

Armata Pharmaceuticals (ARMP) is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections. Its main product candidates, AP-PA02 and AP-SA02, target significant bacterial pathogens.

The addressable markets for Armata Pharmaceuticals' main products or services are:

• AP-PA02 (targeting Pseudomonas aeruginosa respiratory infections, including in Cystic Fibrosis):
• The global Pseudomonas aeruginosa infection treatment market is estimated to be valued at USD 1.41 billion in 2025 and is projected to reach USD 2.51 billion by 2032. Other estimates for the global market include USD 2.18 billion in 2025, expanding to USD 2.86 billion by 2030, and USD 1.47 billion in 2024, projected to reach USD 2.37 billion by 2032.
• The global cystic fibrosis therapeutics market, which includes treatments for Pseudomonas aeruginosa infections in CF patients, was estimated at USD 10.3 billion in 2024 and is projected to reach USD 22.7 billion by 2030. North America held a significant share of this market, accounting for 59.8% of revenue in 2024.
• AP-SA02 (targeting Staphylococcus aureus bacteremia, including Methicillin-resistant Staphylococcus aureus (MRSA)):
• The global methicillin-resistant Staphylococcus aureus (MRSA) drugs market was valued at USD 2.15 billion in 2023. Another report indicates the global MRSA drugs market size was valued at USD 4.1 billion in 2023 and is anticipated to grow to 2032.
• The North American methicillin-resistant Staphylococcus aureus drugs market is anticipated to reach USD 2.6 billion by 2032.

• Advancement and Potential Commercialization of AP-SA02: Armata Pharmaceuticals is progressing its lead therapeutic candidate, AP-SA02, a bacteriophage therapy for *Staphylococcus aureus* bacteremia, toward a pivotal Phase 3 clinical trial in 2026, following positive Phase 2a results. Successful completion of this trial and subsequent regulatory approval could lead to the commercialization of AP-SA02, positioning it as a significant revenue driver.
• Pipeline Expansion and Development of Additional Phage Therapeutics: The company is actively developing a broad pipeline of natural and synthetic phage candidates targeting various antibiotic-resistant pathogens beyond *Staphylococcus aureus*, including *Pseudomonas aeruginosa* (with candidates like AP-PA02 and AP-PA03). Armata completed three critical Phase 2 trials, two in 2024, for distinct phage cocktails designed to treat chronic pulmonary disease and acute systemic bacterial infections, indicating a pathway toward pivotal Phase 3 studies for these programs as well.
• Strategic Collaboration with Merck: Armata Pharmaceuticals has a collaboration agreement with Merck for the development of proprietary synthetic phage candidates aimed at an undisclosed infectious disease agent. This partnership could generate future revenue through milestone payments and royalties if the development programs are successful.
• Non-Dilutive Grant and Award Funding: Armata has been securing non-dilutive funding to support its research and development efforts. For example, in Q1 2025, the company received an additional $4.65 million from a U.S. Department of Defense (DoD) award for its AP-SA02 program, and reported $2.2 million in grant and award revenue in Q2 2025. While not from product sales, this funding contributes to overall revenue and helps advance the pipeline towards commercialization.

Share Issuance

• Armata Pharmaceuticals registered a shelf to sell up to $100,000,000 of securities.
• The company filed a Form S-8 to register an additional 1,811,295 shares of common stock for issuance under its 2016 Equity Incentive Plan and 2016 Employee Stock Purchase Plan.
• Armata's largest funding round in recent years was a Post IPO round for $26.9 million in April 2022.

Inbound Investments

• On August 11, 2025, Armata Pharmaceuticals secured a $15.0 million term loan from Innoviva Strategic Opportunities LLC, maturing on January 11, 2029, with repayment guaranteed by its domestic subsidiaries and secured by substantially all company assets.
• The company received $4.65 million in non-dilutive funding from the U.S. Department of Defense (DoD) in Q1 2025, with the Medical Technology Enterprise Consortium (MTEC) award increased by $5.3 million to $21.6 million in July 2024 and extended into Q3 2025.
• Armata received a $5.0 million Therapeutics Development Award from the Cystic Fibrosis Foundation, with the final payment of $0.3 million received in January 2024.

Capital Expenditures

• Capital expenditures over the last approximately five years have included values such as $0.51 million, $1.88 million, $8.14 million, $2.21 million, $1.30 million, and $0.82 million.
• The average annual capital expenditures growth rate has seen a decrease of -12% over the past three years and -57% over the past five years.
• Capital is primarily directed towards research and development, encompassing clinical trials and the development of cGMP-compliant manufacturing processes for its phage candidates.